Adage Capital Partners’s Pardes Biosciences PRDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-450,000
Closed -$594K – 968
2023
Q1
$594K Hold
450,000
– – ﹤0.01% 815
2022
Q4
$760K Hold
450,000
– – ﹤0.01% 851
2022
Q3
$833K Hold
450,000
– – ﹤0.01% 897
2022
Q2
$1.38M Hold
450,000
– – ﹤0.01% 905
2022
Q1
$3.25M Hold
450,000
– – 0.01% 868
2021
Q4
$7.37M Sell
450,000
-550,000
-55% -$6.4M 0.01% 771
2021
Q3
$10M Hold
1,000,000
– – 0.02% 685
2021
Q2
$10M Hold
1,000,000
– – 0.02% 692
2021
Q1
$10M Buy
+1,000,000
New +$10.3M 0.02% 676

Other funds holding PRDS

Adage Capital Partners's PRDS Position: Q2 2023 in Review

Adage Capital Partners sold out of Pardes Biosciences (PRDS) in Q2 2023, closing a stake of 450,000 shares — an estimated $594K sold.

Adage Capital Partners first reported a position in PRDS in Q1 2021 and held it in 9 quarters. The position peaked at $10M in Q2 2021. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

  • Adage Capital Partners reported no remaining Pardes Biosciences position as of Q2 2023 after selling out during the quarter.
  • Adage Capital Partners sold 450,000 Pardes Biosciences shares in Q2 2023, an estimated $594K.
  • Adage Capital Partners first reported a position in Pardes Biosciences in Q1 2021 and held it in 9 quarters.
  • Adage Capital Partners's Pardes Biosciences position peaked at $10M in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Pardes Biosciences as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.